Navigation Links
Mast Therapeutics Reports First Quarter 2013 Financial Results
Date:5/15/2013

d during 2012.

Selling, general and administrative (SG&A) expenses for the first quarter of 2013 were $2.1 million, an increase of $0.1 million, or 3%, compared to $2.0 million for the same period in 2012. The increase resulted primarily from an increase in personnel costs related to increased headcount.

Balance Sheet HighlightsAs of March 31, 2013, the Company had cash, cash equivalents and short-term investments totaling $32.0 million. Stockholders' equity amounted to $36.6 million as of March 31, 2013. 

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). 

The Company is recruiting subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014.  More information can be found on the Company's web site at www.masttherapeutics.com.

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-lookin
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , September 18, 2014 ... their audience, has updated the incredibly successful Serialisation Countdown ... The interactive PDF, available at pharmaserialisation.com shows ... in which they will be coming into force. ... no longer a matter of "if", but "when" they ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the list ... the Zacks Equity Research analysts discuss the latest news ... recently featured in the blog include the Avanir Pharmaceuticals (Nasdaq: ... NPSP - Free Report ), Orexigen (Nasdaq: ... - Free Report ) and Gilead (Nasdaq: GILD ...
(Date:9/18/2014)... , Sept. 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... , M.D., Ph.D. to the Company,s Board of Directors, ... fills a vacancy on the Board of seven members. ... and Corporate Governance Committee and a member of the ... a member of Neurotrope,s Scientific Advisory Board, a position ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4
... AGAWAM, Mass., June 7, 2011 A free white ... validation of their cleaning processes is available from Microtest ... . As many medical devices are made ... plastics, manufacturers may require the use of various agents ...
... Biomedical Inc., a developer of an advanced implantable vena cava ...  The round was led by Three Arch Partners, which was ... Vena cava filters, which were first introduced ... that can lead to a potentially fatal pulmonary embolism (PE). ...
Cached Medicine Technology:New White Paper Helps Medical Device Manufacturers Validate Cleaning Processes 2Crux Successfully Completes Funding for Advanced Filter for PE Prevention 2
(Date:9/18/2014)... PA (PRWEB) September 18, 2014 "Medical ... patient care while also maintaining the patient's privacy," said ... up with this idea in order to supply caregivers ... well." , They created a prototype for The Helper ... device enables staff to turn patient onto his or ...
(Date:9/18/2014)... 2014 Companies in the Carbon ... selling it to downstream industries in either gas, liquid ... are food and beverage manufacturers. Food producers use carbon ... or pizzas. The gas is also used as a ... to carbonate soft drinks, beer and other beverages. According ...
(Date:9/18/2014)... Daily supplements of selenium or vitamin E don,t seem ... among men, a new study indicates. Previous animal ... prevent cataracts. To investigate this further, William Christen, from ... Boston, and his colleagues examined data from a randomized, ... was initially designed to study prevention of prostate cancer. ...
(Date:9/18/2014)... Lambertville, NJ (PRWEB) September 18, 2014 ... consulting firm, announced today that President and co-founder ... Business Journal’s Innovation Award Winners for 2014, recognizing ... naming him as an emerging executive of the ... health care and life sciences that continue to ...
(Date:9/18/2014)... 18, 2014 Stealth Health Revolution ... advocate, and Frank Davis, founder of Food for ... are pleased to announce the new recipe book, ... delicious, nutrition-packed meals using Activz whole-food powders." ... step in the Stealth Health Revolution ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3
... ... scores to the Centers for Medicare and Medicaid Services , ... Houston, TX (PRWEB) October 6, 2009 -- ... beneficiaries in the counties of Harris, Fort Bend, Montgomery, and Galveston on the Mainland, ...
... , New National Survey Finds Jobless Individuals Four Times ... 6 A new national survey shows the economic downturn is ... who are unemployed are four times as likely as those with ... Americans who experienced involuntary changes in their employment status, such as ...
... Oct. 6 iJET Intelligent Risk Systems, a ... services, today announced the third webinar in its ... Resiliency." These interactive webinars help multinational organizations institute ... their organizations, especially amidst the ongoing effects of ...
... ... gathered recently at the Massachusetts Institute of Technology,s Faculty Club for ... being used to save lives, reduce suffering and extend human potential. ... by Alexander Medvedev, PhD., Vice President, Research & Development, Terumo Heart, ...
... bioTheranostics, a bioMerieux company that discovers, develops and commercializes ... company has signed a two-year agreement with Lab21 to ... in the United Kingdom (UK), Ireland and Middle East ... the terms of the agreement, UK-based Lab21 will market ...
... ... the parts washing industry. Midbrook has extensive experience washing parts and equipment in a variety ... facility to help a North American automotive parts supplier solve a de-rusting issue. , ... (Vocus) October 6, 2009 -- ...
Cached Medicine News:Health News:Local Medicare Advantage Plan Scores High on Diabetic Care and Blood Pressure Control 2Health News:Economic Downturn Taking Toll on Americans' Mental Health 2Health News:Economic Downturn Taking Toll on Americans' Mental Health 3Health News:iJET's 'Survive/Thrive' Webinar Series Continues With 'Pandemic Influenza: Where Do We Stand?' 2Health News:iJET's 'Survive/Thrive' Webinar Series Continues With 'Pandemic Influenza: Where Do We Stand?' 3Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 2Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 3Health News:bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries 2Health News:bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries 3Health News:Midbrook Production Washing A Valuable Partner 2Health News:Midbrook Production Washing A Valuable Partner 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: